Adamis Pharmaceuticals Corporation (ADMP)

$0.1869

+0.00 (+0.70%)
Rating:
Recommendation:
Buy
Symbol ADMP
Price $0.1869
Beta 1.062
Volume Avg. 1.84M
Market Cap 28.032M
Shares () -
52 Week Range 0.12-0.85
1y Target Est -
DCF Unlevered ADMP DCF ->
DCF Levered ADMP LDCF ->
ROE -246.15% Strong Sell
ROA -261.98% Strong Sell
Operating Margin -
Debt / Equity 321.03% Strong Buy
P/E -0.68
P/B 9.85 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ADMP news


Dr. Dennis Carlo
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose. It also offers APC400, a tempol gel use of reducing radiation dermatitis in patients undergoing treatment for cancer; and APC410 for the treatment of respiratory diseases, including asthma, respiratory syncytial virus, influenza, and COVID-19. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables; and veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation was founded in 2006 and is headquartered in San Diego, California.